-
Perrigo, Synthon to launch generic Xyzal
ALLEGAN, Mich. — The Food and Drug Administration has granted market exclusivity for a generic version of a medication designed to treat indoor and outdoor allergies.
Perrigo said Monday that its licensor and supplier Synthon received regulatory approval for levocetirizine tablets, a generic version of UCB/Sepracor's Xyzal, which is marketed in the United States by Sanofi-Aventis.
The levocetirizine tablet is the only approved generic product having a label containing all indications, Perrigo said.
-
Perrigo introduces generic Aleve Liquid Gels
ALLEGAN, Mich. — Perrigo on Monday launched a store-brand version of Bayer Healthcare’s Aleve Liquid Gels, 220 mg.
Aleve Liquid Gels generated annual sales of approximately $80 million, Perrigo stated, citing SymphonyIRI Group data.
"This approval is another example of Perrigo's commitment to bring new products to market,” stated Perrigo's chairman and CEO Joseph Papa. Perrigo noted that it is the first-to-market with a generic equivalent of the Aleve Liquid Gels.